Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials.

ABSTRACT: Determining the duration of immunity induced by booster doses of CoronaVac is crucial for informing recommendations for booster regimens and adjusting immunization strategies. In two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, immunogenicity and safety of four immunization regimens are assessed in adults aged 18 to 59 years and one immunization regimen in adults aged 60 years and older, respectively. Serious adverse events occurring within 6 months after booster doses are recorded as pre-specified secondary endpoints, geometric mean titres (GMTs) of neutralising antibodies one year after the 3-dose schedule immunization and 6 months after the booster doses are assessed as pre-specified exploratory endpoints, GMT fold-decreases in neutralization titr

SUBMITTER: Xin Q 

PROVIDER: S-EPMC9166693 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature